# A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

> **NCT00269750** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 100 (—)

## Conditions studied

- Urge Incontinence

## Interventions

- **DRUG:** OROS® oxybutynin or Ditropan®

## Key facts

- **NCT ID:** NCT00269750
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** —
- **Final completion:** 1997-02
- **Target enrollment:** 100 (—)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269750, "A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00269750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*